Global Pemphigus Vulgaris - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035

Global Pemphigus Vulgaris Market Outlook

Thelansis's "Global Pemphigus Vulgaris Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pemphigus Vulgaris treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Pemphigus Vulgaris Overview

Pemphigus vulgaris is a rare, potentially life-threatening autoimmune blistering disease in which antibodies attack proteins responsible for holding skin cells together, causing painful blistering and erosion across the skin and mucous membranes that can become extensive without treatment. For most of the modern treatment era, care relied on high-dose corticosteroids paired with various immunosuppressants, an approach that could control the disease but often at the cost of significant long-term side effects. That changed when a B-cell depleting antibody therapy became the first biologic approved for the condition, a genuine milestone after decades without a major treatment advance, and it is now recommended alongside corticosteroids as first-line therapy based on trial evidence showing meaningfully better outcomes than steroids alone. What makes pemphigus somewhat unusual within antibody-mediated autoimmune disease is that this success has been difficult to replicate, with newer mechanisms that succeeded in closely related conditions failing to show similar benefit here, prompting renewed interest in why trial outcomes diverge.

Key Highlights

• In Germany, prevalent Pemphigus Vulgaris (PV) cases are projected to increase from 7,972 in 2025 to 11,793 by 2035.
• Pemphigus Vulgaris is a rare autoimmune blistering disease causing painful skin and mucosal lesions.
• Despite available immunosuppressive therapies, disease relapse and treatment-related adverse effects remain major challenges.
• Significant unmet need remains for targeted therapies that provide durable disease control.

Market Overview

• The Spain Pemphigus Vulgaris market is projected to grow from $12M in 2025 to $26M by 2035.
• Market growth is driven by:
• Increasing adoption of biologic and targeted immunotherapies
• Improved diagnosis and disease management
• Future growth will depend on therapies offering sustained remission with improved safety profiles.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Cabaletta Bio